THE EFFICACY OF ROSUVASTATIN IN THE TREATMENT OF CORONARY HEART DISEASE IN ELDERLY PATIENTS AFTER PERCUTANEOUS INTERVENTION

Abstract

Epidemiological studies have shown that the increased levels of low-density lipoprotein (LDL-C), triglycerides (TG) and very low-density lipoproteids (VLDL-C) and the decrease in the high-density lipoproteins (HDL-C) are among the most powerful risk factors for CVD. The introduction of statins into clinical practice in the late 80s of the last century made it possible to significantly affect mortality from CVD. The meta-analysis of 10 large-scale studies, which included about 80 thousand patients, showed that this class of the drugs provides for the reduction in the frequency of cardiovascular events by 27%, stroke - by 18%, and overall mortality - by 15%.
This article is devoted to the study of the rosuvastatin efficacy in elderly patients with coronary artery disease who underwent percutaneous intervention (PCI). The data obtained indicate the effective impact of the studied drug on blood lipid composition, the decrease in mortality, coronary artery restenosis, MI, and the number of re-hospitalizations in elderly patients with coronary artery disease after PCI.